The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of nivolumab plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC): 4-year (yr) follow-up from CheckMate 649 (CM 649).
 
Daniel Lin
Stock and Other Ownership Interests - BioNano Genomics
Honoraria - Exelixis
Consulting or Advisory Role - Exelixis; Exelixis; Exelixis/Ipsen
 
Wenying Quan
No Relationships to Disclose
 
Marné Garretson
No Relationships to Disclose
 
Viktor Chirikov
Employment - OPEN Health
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb/Celgene (Inst)
 
Clara Chen
Employment - AstraZeneca; AstraZeneca; Bristol-Myers Squibb/Celgene
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene
 
Prianka Singh
Employment - Bristol Myers Squibb
 
Catherine Davis
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Ryan Sugarman
No Relationships to Disclose